治疗前AMH提示PCOM者化疗后卵巢储备仍较高但卵泡丢失程度相似
该研究纳入467例接受烷化剂治疗的乳腺癌或血液恶性肿瘤年轻女性,按基线AMH水平分为PCOM样组与非PCOM组,纵向随访24个月。结果显示PCOM组卵泡丢失程度与非PCOM组相似,但在12和24个月时AMH显著更高,且月经功能恢复更快。
要点
- PCOM样AMH并不能防止化疗所致卵泡丢失,两组卵泡丢失程度相似。
- PCOM组在化疗结束后12和24个月AMH显著高于非PCOM组。
- PCOM组月经功能恢复更快,但仅部分恢复基线AMH值。
核心结论
- 治疗前AMH提示PCOM的年轻女性接受烷化剂化疗后卵泡丢失程度与低AMH者相似,仅部分恢复基线值,但长期AMH水平显著更高且月经功能恢复更快。
研究设计与样本
- 本研究为法国里尔大学医院OncoFertility Observatory于2012年1月至2022年2月开展的回顾性分析,数据来自前瞻性收集的467例接受烷化剂治疗的乳腺癌或血液恶性肿瘤女性。
主要发现
- 最终分析纳入195例乳腺癌和125例血液恶性肿瘤患者,乳腺癌PCOM组年龄更小(P=0.002)、基线月经紊乱发生率更高(P=0.003)、激素受体阳性肿瘤更多(P=0.04)。
- 乳腺癌和血液恶性肿瘤中,PCOM组治疗前窦卵泡计数均显著高于非PCOM组(37.8±14.7 vs 17.3±9.4;P≤0.001和33.6±12.4 vs 19.3±8.4;P≤0.001)。
- 调整年龄、BMI、吸烟和口服避孕药后,PCOM组在随访12和24个月时AMH值仍显著更高。
- 随访结束时乳腺癌组AMH不可测比例PCOM组为8.3%、非PCOM组为30.4%(P=0.0072),血液恶性肿瘤组无显著差异(18.7% vs 29.9%;P=0.55)。
- 血液恶性肿瘤组仅3例PCOM组女性恢复治疗前AMH值,乳腺癌组无女性恢复初始AMH值。
关键数值与推荐
- PCOM样AMH阈值:2016年前≥35 pmol/l,2016年后≥30 pmol/l;非PCOM组为8≥AMH<35 pmol/l。
- AMH在化疗结束后12至24个月间趋于平台:乳腺癌调整后log AMH平均差0.2(95%CI -0.2至0.5),血液恶性肿瘤0.5(95%CI -0.1至1.1)。
- 乳腺癌组持续闭经发生率在12个月时非PCOM组显著更高(2% vs 12%;P=0.043),24个月时无显著差异。
- 血液恶性肿瘤组持续闭经发生率PCOM组 tended lower但未达显著(13.3% vs 30.4%;P=0.22)。
临床怎么用
- 所有接受烷化剂方案的女性均应系统提供生育力保存和生物/临床随访,不论治疗前AMH水平如何。
- 高卵巢卵泡储备并不能排除显著卵泡丢失,不能因AMH提示PCOM而放松卵巢功能监测。
局限性
- 回顾性设计无法区分多囊卵巢综合征与仅PCOM,因肿瘤背景下基线未常规检测雄激素水平。
- 诊断时50%女性使用口服避孕药,可能低估AMH高于35 pmol/l的患者数量。
- 纳入周期长导致使用两种AMH检测方法,但已采用验证并调整的PCOM诊断阈值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Are young women with anti-Müllerian hormone (AMH) levels suggesting polycystic ovarian morphology (PCOM) at baseline better protected against chemo-induced ovarian damages? SUMMARY ANSWER: Compared with women with lower baseline AMH levels, women with pre-treatment AMH levels suggesting PCOM experienced a similar degree of follicular loss and only partial recovery of baseline values after treatment but maintained significantly higher AMH levels at 12 and 24 months of follow-up and had a faster menstrual function resumption. WHAT IS KNOWN ALREADY?: Longitudinal studies on AMH variations in women treated by chemotherapy have shown that pre-treatment AMH levels is one of the factors influencing the degree of the ovarian recovery. Recombinant AMH administration recently demonstrated a protective effect on ovarian follicles exposed to alkylating agents in mouse models. High AMH levels in women with polycystic ovaries have been associated with decreasing apoptosis of granulosa cells in small follicles and altered initial follicular growth. STUDY DESIGN, SIZE, DURATION: This retrospective analysis of prospective collected data was carried out at the OncoFertility Observatory of the Lille University Hospital from January 2012 to February 2022. All women eligible for chemotherapy are prospectively recruited for ovarian function indicators follow-up until 24 months after the end of treatment. PARTICIPANTS/MATERIALS, SETTING, METHODS: 467 women treated by alkylating agents for breast cancer (BC) or hematological malignancies (HM) were included in our Onco-Fertility Observatory and benefited from an onco-fertility consultation with discussion on fertility preservation options. The study population was divided into two groups according to basal AMH level at time of diagnosis: PCOM-like AMH levels ≥35 pmol/l before 2016 and ≥ 30 pmol/l after 2026 (PCOM group), and 8 ≥ AMH <35 pmol/l (non-PCOM group). Serial AMH measurements were performed at baseline before chemotherapy initiation (AMH0), 15 days after the start of chemotherapy (AMH1), 15 days before the last chemotherapy cycle (AMH2), and at time 3, 6, 12, 18, and 24 months from the end of chemotherapy. Menstrual function was assessed in parallel and antral follicle count (AFC) was performed at baseline, 12- and 24-month post-treatment. Serum AMH levels were measured using the second-generation enzyme immunoassay EIA AMH/MIS kit from 2012 to 2016, and by an automated AMH immunoassay on an Access Dxi analyzer thereafter. Results were secondarily homogenized using a validated conversion formula. MAIN RESULTS AND THE ROLE OF CHANCE: 261 BC women aged 31.4 years, and 206 HM patients aged 24.4 years eligible for alkylating regimen were included before commencing treatment. Sixty-six women in the BC population were excluded from this study (death n = 4, recurrence n = 7, lost to follow-up n = 55) and 81 in the HM population (death n = 6, lost of follow-up n = 46, pregnancies n = 2, oophorectomy for cryopreservation n = 27). A total of 195 BC and 125 HM patients completed the whole follow-up and were finally analyzed. In BC group, women with PCOM were significantly younger (P = 0.002), had a higher incidence of menstrual disturbances at baseline (P = 0.003) and had more frequently a hormone receptor-positive (HR+) tumor (P = 0.04). In HM group, PCOM women were not significantly different from non-PCOM women concerning general characteristics. In BC and HM groups, pre-treatment AFC was significantly higher in PCOM group versus non-PCOM (37.8 ± 14.7 vs 17.3 ± 9.4; P ≤ 0.001 and 33.6 ± 12.4 vs 19.3 ± 8.4; P ≤ 0.001, respectively). In BC, as in HM population, a depletion phase can be distinguished from the beginning to the end of chemotherapy (AMH0-AMH2) and a recovery phase from the end of chemotherapy (AMH2) to the time +12 months followed by a sustaining phase between time +12 and 24 months. In BC as in HM population, before and after adjustment for the confounding variables (age, BMI, smoking and oral contraceptive (OC) use prior to chemotherapy), AMH values in the PCOM group remained significantly higher at time +12 and +24 months of follow-up. In BC PCOM subgroup, the AMH depletion slope was steeper and followed by a faster and higher AMH increase after the end of treatment, while no difference was observed between PCOM and non-PCOM HM women. In both cancer groups and in both subgroups of AMH levels, AMH values plateaued between Time +12 and Time +24 months (adjusted mean difference in log AMH (95% CI) 0.2 (-0.2 to 0.5) in BC population; 0.5 (-0.1 to 1.1) in HM population). At the end of follow-up, the frequency of undetectable AMH values in BC was 8.3% in PCOM versus 30.4% in non-PCOM (P = 0.0072) whereas, in HM group, there was no significant difference (18.7% vs 29.9%; P = 0.55). In HM, only three women, all from the PCOM group, recovered their pre-treatment values at the end of follow-up. In BC, none of the women recovered their initial AMH values. Clinically, the incidence of persistent amenorrhea at time +12months in HM subgroup tended to be lower in PCOM than in non-PCOM women but did not reach significance (13.3% vs 30.4%; P = 0.22). In BC subgroup, the incidence of persistent amenorrhea was significantly higher in non-PCOM women at time +12 months (2% vs 12%; P = 0.043) but no longer at time + 24 months. LIMITATIONS, REASONS FOR CAUTION: the retrospective design of this study did not allow us to differentiate women with PCOS from women with PCOM only, as androgen levels were not routinely measured at baseline in this oncologic setting. The high incidence of women under OC at diagnosis (50%) may have underestimated the number of patients with AMH levels higher than 35 pmol/l. Two methods of AMH assays were used due to the long duration of the inclusion period but with validated and adapted cut-offs levels for the diagnosis of PCOM. WIDER IMPLICATIONS OF THE FINDINGS: Fertility preservation and biological/clinical follow-up should be systematically offered to all women undergoing alkylating regimen, irrespective of their pre-treatment AMH level as very high ovarian follicular content does not preclude to significant follicle loss. A better understanding of the role of AMH in ovaries facing chemotherapy may ultimately help in developing ovarioprotective drugs. FUNDING: This work was supported by Agence Régionale de Santé Hauts de France and Agence Onco Hauts-de-France who provided finances for AMH dosages (no. DOS/SDES/AR/FIR/2019/282). DISCLOSURES: No competing interests. TRIAL REGISTRATION NUMBER: DC-2008-642 and CNIL DEC2015-112.
引用
- Decanter C, Legrand C, Behal H, et al. Pre-treatment AMH levels suggesting PCOM do not prevent chemotherapy-induced ovarian damage despite higher long-term ovarian reserve: a longitudinal study in 467 women treated with alkylating agents. Hum Reprod. 2026. PMID: 42600055. doi:10.1093/humrep/deag131
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。